Market Research Logo

Country Overviews Market Research Reports & Industry Analysis


Country Overviews Industry Research & Market Reports

  • Costa Rica Pharmaceuticals & Healthcare Q4 2018

    ... offers superior market access and development opportunities to multinationals based on factorssuch as continuous improvement in healthcare infrastructure and government commitment to upholding an attractive businessenvironment. Additionally, the demand for innovative medicines will still need ... Read More

  • Europe Pharmaceuticals & Healthcare Q4 2018

    ... to region-specific trends. Themore developed Western markets will continue to be favoured by innovative drugmakers due to stronger regulatory oversight andgreater purchasing power, although growth in these markets will be suppressed by aggressive cost-containment. Revenue ... Read More

  • Ghana Pharmaceuticals & Healthcare Q4 2018

    ... has led to difficulties doingbusiness, including high operational costs for foreign companies. While Ghana is positioned as one of the more attractivepharmaceutical markets for multinational firms on a regional basis, generic products will maintain a ... Read More

  • Hong Kong Pharmaceuticals & Healthcare Q4 2018

    ... cope with a rapidly ageing population. On the private side too, the government has beenpromoting the development of private hospitals as part of its reform initiatives to improve the long-term sustainability of thecountry’s healthcare system. Read More

  • Latin America Pharmaceuticals & Healthcare Q4 2018

    ... for multinational pharmaceutical firms with a risingburden of chronic diseases and increasing access to healthcare services. However, in the short-term growth opportunities in theregion's major markets will be repressed by significant political and economic risks. Read More

  • Sub-Saharan Africa Pharmaceuticals & Healthcare Q4 2018

    ... within the generic medicines sector, while the larger, moredeveloped markets present viable opportunities for patented medicine sales in urban regions. Cooperative agreements withinternational firms will provide opportunities for domestic firms to expand their manufacturing capacities. Read More

  • Middle East And North Africa Pharmaceuticals & Healthcare Q4 2018

    ... opportunities for multinational drugmakers looking to expand to emergingmarkets. Heightened industry and country risk dissuade company interest and the larger markets dominate multinational activityfor patented medicine sales. Ample opportunities exist in the generics market segment. Read More

  • Algeria Pharmaceuticals & Healthcare Q1 2019

    ... and healthcare industries willcontinue to create investment opportunities, despite the slow progress in improving the regulatory environment. Despite sustaineddevelopment of local drug manufacturing capacity - which is in part driven by foreign direct investment and ... Read More

  • Cameroon Pharmaceuticals & Healthcare Q1 2019

    ... Although the health system and pharmaceutical sector willcontinue to gradually develop, low spending per capita on medicine and a poor operating environment will continue to weigh onopportunities presented to drugmakers in the short term. The ... Read More

  • France Pharmaceuticals & Healthcare Q1 2019

    ... recent commitments towards accelerating marketauthorisation of innovative medicines, as well as optimising market access and promoting innovation and clinical research,anticipate an effort to transform France into a highly attractive market for drugmakers and investors, reversing ... Read More

  • United Arab Emirates Pharmaceuticals & Healthcare Q1 2019

    ... expansion of private healthcare coverage and the modernisationof health infrastructure will contribute to drive prescription market growth. Stricter pricing controls, generic drug substitution and anunfavourable demographic profile will act act headwinds to firms over the ... Read More

  • Asia Pharmaceuticals & Healthcare Q4 2018

    ... However, these markets will no longer providesignificant revenue growth due to aggressive cost-containment. Instead, growth opportunities will be plentiful in emerging markets.We note that due to continued regulatory challenges and a growing focus on cost-efficiency, ... Read More

  • El Salvador Pharmaceuticals & Healthcare Q4 2018

    ... for pharmaceutical investment. Despite this, a steady number ofcollaborations with international organisations and businesses is improving the standard of healthcare and raising the long-termgrowth prospects of the country's low penetration of pharmaceuticals and medical equipment. Read More

  • Germany Pharmaceuticals & Healthcare Q4 2018

    ... to services, will continue tosupport this potential. However, we do caution that market access is now challenging, as authorities use a range of cost-containment measures and downward price pressures as a means of controlling state ... Read More

  • Nicaragua Pharmaceuticals & Healthcare Q4 2018

    ... pharmaceutical companies operating in thecountry. Furthermore, the ongoing political crisis and heightened social unrest will exacerbate the risks associated with Nicaragua,further deterring multinational drugmakers from investing in what is already one of the least attractive ... Read More

  • Uganda Pharmaceuticals & Healthcare Q4 2018

    ... remain dominant, while the government plans to localisedrug production to boost medicine sustainability. While the market has brighter long-term prospects, multinational drugmakerappetite will remain subdued despite the positive economic growth forecast over the coming years. Read More

  • Global Pharmaceuticals & Healthcare Q4 2018

    ... face increasingly protectionist policies in emerging markets.These policies can be divided into localisation requirements and investment incentives, including subsidies and tariffs.Multinational pharmaceutical firms must assess their market entry strategy to reflect each market's individual protectioniststance. Read More

  • India Pharmaceuticals & Healthcare Q1 2019

    ... the major emergingmarket for multinational pharmaceutical firms. Moreover, healthcare reforms bode well for pharmaceutical market development.Despite this, a tough pricing environment and low levels of intellectual property protection will remain ongoing concerns formultinational pharmaceutical firms. Read More

  • Kenya Pharmaceuticals & Healthcare Q1 2019

    ... or distributors. Authorities are also investing in regulatoryimprovement initiatives, which will complement their efforts to achieve universal healthcare coverage. On the other hand, someforeign players may remain weary of committing to the market due to ... Read More

  • Peru Pharmaceuticals & Healthcare Q1 2019

    ... profiles support the use of chronic treatments and a variety ofhealthcare services, including diagnostic. However, the fact that the government remains the key source of healthcare funding willcontinue to pose risks to the market's development. Read More

  • Pharmaceuticals in Australia

    ... national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market ... Read More

  • Xilinx Inc (XLNX) - Financial and Strategic SWOT Analysis Review

    ... you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ... Read More

  • Azerbaijan Pharmaceuticals & Healthcare Q4 2018

    ... pharmaceutical market, we remain cautious about its commercial attractiveness to multinationals, at least in theshort term. The over-reliance on out-of-pocket payments has made the market vulnerable to economic fluctuations, especiallygiven its reliance on imported medicines. Read More

  • Namibia Pharmaceuticals & Healthcare Q4 2018

    ... and efficiency issues within the public healthcare sector. The small middle-and upper-class segments provide pockets of demand for innovative medicines, which will continue to be imported by key regionalplayers and representative offices of established multinationals. Read More

  • Panama Pharmaceuticals & Healthcare Q4 2018

    ... system inefficiencies will continueto weigh on the country’s ability to improve access to healthcare. Sustained pro-growth economic policies and the Panama Canalwill continue to support the country’s position as a logistic and export hub, including ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog